The impact of edema on planning 125I and 103Pd prostate implants

被引:53
|
作者
Yue, N
Dicker, AP
Nath, R
Waterman, FM
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA
关键词
brachytherapy; prostate implants; I-125; Pd-103; edema; dose evaluation; preimplant planning;
D O I
10.1118/1.598585
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Permanent transperineal interstitial I-125 and Pd-103 prostate implants are generally planned to deliver a specific dose to a clinically defined target volume; however, the post-implant evaluation usually reveals that the implant delivered a lower or higher dose than planned. This difference is generally attributed to such factors as source placement errors, overestimation of the prostate volume on CT, and post-implant edema. In the present work we investigate the impact of edema alone. In routine prostate implant planning, it is customary to assume that both the prostate and seeds are static throughout the entire treatment time, and post-implant edema is not taken into consideration in the dosimetry calculation. However, prostate becomes edematous after seed implantation, typically by 50% in volume [Int. J. Radiat. Oncol., Biol., Phys. 41, 1069-1077 (1998)]. The edema resolves itself exponentially with a typical half-life of 10 days. In this work, the impact of the edema-induced dynamic change in prostate volume and seed location on the dose coverage of the prostate is investigated. The total dose delivered to the prostate was calculated by use of a dynamic model, which takes edema into account. In the model, the edema resolves exponentially with time, as reported in a separate study based on serial CT scans [Int. J. Radiat. Oncol., Biol., Phys. 41, 1069-1077 (1998)]. The model assumes that the seeds were implanted exactly as planned, thus eliminating the effect of source placement errors. Implants based on the same transrectal ultrasound (TRUS) images were planned using both I-125 and Pd-103 sources separately. The preimplant volume and planned seed locations were expanded to different degrees of edema to simulate the postimplant edematous prostate on day 0. The model calculated the dose in increments of 24 h, appropriately adjusting the prostate volume, seed locations, and source strength prior to each time interval and compiled dose-volume histograms (DVH) of the total dose delivered. A total of 30 such DVHs were generated for each implant using different combinations of edema half-life and magnitude. In addition, a DVH of the plan was compiled in the conventional manner, assuming that the prostate volume and seeds were static during treatment. A comparison of the DVH of the static model to the 30 edema corrected DVHs revealed that the plan overestimated the total dose by an amount that increased with the magnitude of the edema and the edema half-life. The maximum overestimation was 15% for I-125 and 32% for (103)pd. For more typical edema parameters (a 50% increase in volume and a 10 day half-life) the static plan for I-125 overestimated the total dose by about 5%, whereas that for Pd-103 overestimated it by about 12%. (C) 1999 American Association of Physicists in Medicine. [S0094-2405(99)00705-1].
引用
收藏
页码:763 / 767
页数:5
相关论文
共 50 条
  • [41] New national air-kerma-strength standards for 125I and 103Pd brachytherapy seeds
    Seltzer, SM
    Lamperti, PJ
    Loevinger, R
    Mitch, MG
    Weaver, JT
    Coursey, BM
    JOURNAL OF RESEARCH OF THE NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY, 2003, 108 (05) : 337 - 358
  • [42] A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate
    Yue, N
    Dicker, AP
    Corn, BW
    Nath, R
    Waterman, FM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (02): : 447 - 454
  • [43] A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd
    Antipas, V
    Dale, RG
    Coles, IP
    PHYSICS IN MEDICINE AND BIOLOGY, 2001, 46 (10): : 2557 - 2569
  • [44] Treatment-planning considerations for prostate implants with the new linear RadioCoil™ 103Pd brachytherapy source
    Meigooni, Ali S.
    Awan, Shahid B.
    Rachabatthula, Venkata
    Koona, Rafiq A.
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2005, 6 (03): : 23 - 36
  • [45] 前列腺癌125I和103Pd粒子植入治疗疗效比较
    刘峰
    王俊杰
    中国肿瘤临床与康复, 2007, (01) : 76 - 78
  • [46] Study for the radial dose function of 131Cs, 125I and 103Pd brachytherapy seeds sources
    Wang, Jian-Hua
    Qiu, Xiao-Ping
    Liu, Wei
    Xu, Xun-Jiang
    Hedianzixue Yu Tance Jishu/Nuclear Electronics and Detection Technology, 2007, 27 (06): : 1223 - 1226
  • [47] 125I versus 103Pd for low-risk prostate cancer:: Preliminary PSA outcomes from a prospective randomized multicenter trial
    Wallner, K
    Merrick, G
    True, L
    Sutlief, S
    Cavanagh, W
    Butler, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05): : 1297 - 1303
  • [48] Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy
    Chen, CT
    Waterman, FM
    Valicenti, RK
    Gomella, LG
    Strup, SE
    Dicker, AP
    INTERNATIONAL JOURNAL OF CANCER, 2001, 96 : 83 - 88
  • [49] A calculation of the relative biological effectiveness of 125I and 103Pd brachytherapy sources using the concept of proximity function
    Wuu, CS
    Zaider, M
    MEDICAL PHYSICS, 1998, 25 (11) : 2186 - 2189
  • [50] Effect of improved TLD dosimetry on the determination of dose rate constants for 125I and 103Pd brachytherapy seeds
    Rodriguez, M.
    Rogers, D. W. O.
    MEDICAL PHYSICS, 2014, 41 (11)